Abstract
Background COVID-19 has caused severe outbreaks in Canadian long-term care facilities (LTCFs).
Objective To evaluate the effect of mitigation measures in LTCFs including routine testing of staff and vaccination of staff and residents.
Design Agent-based transmission model parameterized with disease-specific estimates, temporal sensitivity of nasopharyngeal (NP) and saliva testing, preliminary results of vaccine efficacy trials, and data from initial COVID-19 outbreaks in LTCFs in Ontario, Canada.
Setting Characteristics of staff and residents were included in the model with age-dependent risk of hospitalization and deaths, calibrated to the cumulative incidence of COVID-19 reported in these settings.
Participants Synthetic staff and resident populations.
Interventions Routine NP and saliva testing of staff; vaccination of residents and staff.
Measurements Daily incidence and attack rates in the LTCF using large-scale model simulations; estimates of hospitalizations and deaths and their 95% credible intervals.
Results Weekly routine testing of staff with 2-day turnaround time reduced infections among residents by at least 20.3% (95% CrI: 18.7-21.8%), compared to baseline measures of mask-wearing, symptom screening, and staff cohorting alone. A similar reduction of hospitalizations and deaths was achieved in residents. Vaccination averted 2-4 times more infections in both staff and residents as compared to routine testing, and markedly reduced hospitalizations and deaths among residents by 81.4% (95% CrI: 80.6-82.2%), and 82.1% (95% CrI: 81.5-82.7%), respectively.
Limitations Timelines of vaccine distribution and compliance rates with routine testing are key parameters affecting strategy outcomes.
Conclusion Routine testing of staff reduces silent transmission in LTCFs. Vaccination could have a substantial impact on mitigating disease burden among residents, but may not eliminate the need for other measures before population-level control of COVID-19 is achieved.
Competing Interest Statement
Dr. Joanne M. Langley reports that her institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen and Pfizer. Dr. Joanne M. Langley also holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. Other authors declare no competing interests.
Funding Statement
Seyed Moghadas: CIHR (OV4-170643), COVID-19 Rapid Research; Natural Sciences and Engineering Research Council of Canada; and Canadian Foundation for Innovation. Alison Galvani: NSF (RAPID-2027755), NIH (1RO1AI151176-01). Thomas N. Vilches: São Paulo Research Foundation (FAPESP), grant 2018/24811-1. Lauren Cipriano: Society for Medical Decision Making COVID-19 Decision Modeling Initiative funded by the Gordon and Betty Moore Foundation through Grant GBMF9634 to Johns Hopkins University and a Western University Catalyst Research Grant. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the York University Ethics Review Board (Project: 2020-269). The study was categorized as minimal risk, with no requirement for individual consent or participation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The computational model was implemented in Julia language and is available at: https://github.com/thomasvilches/LTCF-covid.
